What is the current valuation of the RNA based-therapeutics market in Spain?

The overall market valuation was $366.32 Million in 2024. Read More

What is the projected market valuation for RNA based-therapeutics in Spain by 2035?

The projected valuation for 2035 is $702.78 Million. Read More

What is the expected CAGR for the RNA based-therapeutics market in Spain during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.1%. Read More

Which technology segment is expected to have the highest valuation in the RNA based-therapeutics market?

The mRNA Therapeutics segment is projected to range from $150.0 Million to $300.0 Million. Read More

What are the key applications driving the RNA based-therapeutics market in Spain?

Key applications include Oncology, Cardiovascular Diseases, Infectious Diseases, and Genetic Disorders. Read More

Which delivery method is anticipated to dominate the RNA based-therapeutics market?

Viral Vectors are expected to have a valuation between $120.0 Million and $250.0 Million. Read More

What is the market size for pharmaceutical companies involved in RNA based-therapeutics in Spain?

The market size for pharmaceutical companies is projected to range from $150.0 Million to $290.0 Million. Read More

Who are the leading players in the RNA based-therapeutics market in Spain?

Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals. Read More

What is the valuation range for the RNA interference technology segment?

The RNA Interference segment is valued between $50.0 Million and $100.0 Million. Read More

How does the market for RNA based-therapeutics in Spain compare to other regions?

While specific regional comparisons are not provided, the growth trajectory suggests a robust development in Spain's RNA based-therapeutics market. Read More

Spain RNA-based Therapeutics Market

ID: MRFR/Pharma/50898-HCR

200 Pages

Nidhi Mandole

Last Updated: February 06, 2026

Spain RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth Outlook & Industry Forecast 2025 To 2035

English

Spain RNA-based Therapeutics Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Technology (USD Million)
  1. 4.1.1 RNA Interference
  2. 4.1.2 Antisense Oligonucleotides
  3. 4.1.3 mRNA Therapeutics
  4. 4.1.4 CRISPR Technology
2. 4.2 Life Sciences, BY Application (USD Million)
  1. 4.2.1 Oncology
  2. 4.2.2 Infectious Diseases
  3. 4.2.3 Genetic Disorders
  4. 4.2.4 Cardiovascular Diseases
3. 4.3 Life Sciences, BY End Use (USD Million)
  1. 4.3.1 Pharmaceutical Companies
  2. 4.3.2 Research Institutions
  3. 4.3.3 Contract Research Organizations
4. 4.4 Life Sciences, BY Delivery Method (USD Million)
  1. 4.4.1 Liposomes
  2. 4.4.2 Nanoparticles
  3. 4.4.3 Viral Vectors
  4. 4.4.4 Electroporation
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Moderna (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 BioNTech (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Alnylam Pharmaceuticals (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Ionis Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sangamo Therapeutics (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 CureVac (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Arcturus Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Translate Bio (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SPAIN MARKET ANALYSIS BY TECHNOLOGY
3. 6.3 SPAIN MARKET ANALYSIS BY APPLICATION
4. 6.4 SPAIN MARKET ANALYSIS BY END USE
5. 6.5 SPAIN MARKET ANALYSIS BY DELIVERY METHOD
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TECHNOLOGY, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY END USE, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END USE, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DELIVERY METHOD, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
  4. 7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Spain Life Sciences Market Segmentation

Life Sciences By Technology (USD Million, 2025-2035)

RNA Interference
Antisense Oligonucleotides
mRNA Therapeutics
CRISPR Technology

Life Sciences By Application (USD Million, 2025-2035)

Oncology
Infectious Diseases
Genetic Disorders
Cardiovascular Diseases

Life Sciences By End Use (USD Million, 2025-2035)

Pharmaceutical Companies
Research Institutions
Contract Research Organizations

Life Sciences By Delivery Method (USD Million, 2025-2035)

Liposomes
Nanoparticles
Viral Vectors
Electroporation

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”